OTC · Biotechnology

Biotest AG (BIESF) Stock

$32.00 +0.00% OTC: BIESF Healthcare

Biotest Aktiengesellschaft, a German biopharmaceutical company established in Dreieich in 1946, specializes in the research, development, production, and global commercialization of advanced biological therapeutics. Its operations are organized into key segments: Therapy, Plasma & Services, and Other.

Valuation

MetricValue
Price$32.00
Market Cap$1.60B
P/E Ratio48.06
P/B Ratio2.40
P/S Ratio2.18
EPS (TTM)$0.67
52-Week High$32.00
52-Week Low$30.48
Dividend Yield0.16%

Financials & Margins

MetricValue
ROE5.13%
ROA1.84%
ROCE7.42%
Gross Margin30.82%
Operating Margin13.01%
Net Margin3.64%
Debt/Equity1.13
Current Ratio5.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$516.0M$516.0M$685.0M$726.0M$649.0M
Operating Profit$-47.0M$-17.0M$144.0M$95.0M$-49.0M
Net Profit$-63.0M$-32.0M$127.0M$26.0M$-71.0M
EPS$-1.60$-0.80$3.21$0.71$-1.79
Op Margin-9.1%-3.2%21.0%13.0%-7.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$1.2B$1.4B$1.4B$1.5B
Total Liabilities$724.0M$832.0M$912.0M$903.0M$1.1B
Cash$104.0M$117.0M$108.0M$108.0M$108.0M
Borrowings$496.0M$574.0M$614.0M$597.0M$831.0M

Latest News

RedBox Storage Completes Portfolio Acquisition, Expanding Hong Kong Footprint with Doubled Operating Network PR Newswire · Jul 16, 2026 USPTO Launches AI Image Search in Trademark Search System, Powered by Clarivate PR Newswire · Jul 16, 2026 POLYTECH Announces the approval of updated process for Microthane®* PR Newswire · Jul 16, 2026 SingWealth Holdings Expands Regional Presence with PFP Capital Limited Launch in Hong Kong PR Newswire · Jul 16, 2026 SWISSto12 Closes US$70 Million Series C to Meet Growing Multi-Orbit Demand Business Wire · Jul 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$34.0M$-40.0M$-3.0M$61.0M$-144.0M
Investing Cash Flow$-42.0M$-66.0M$-32.0M$-54.0M$-21.0M
Financing Cash Flow$4.0M$-10.0M$2.0M$-6.0M$-13.0M
Net Cash Flow$33.0M$12.0M$-8.0M$0$3.0M
Free Cash Flow$16.0M$-70.0M$-36.0M$32.0M$-155.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.42
EV / EBITDA17.22
FCF Yield2.03%
Quick Ratio2.06
Interest Coverage2.97
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held43.20%
Institutions Held0.46%
Institutions Float Held0.80%
Institutional HolderSharesReport Date
SPDR (R) Portfolio Europe ETF2142024-05-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BITGFBiotage AB (publ) $15.01 +0.00% 40.34 $1.20B 1.13%
CKDXFCeryvyn Therapeutics Limited $0.01 +0.00% 0.06 $13.68M 0.00%
CMPUYCompuGroup Medical SE & Co. KGaA $23.00 -7.26% 33.82 $1.19B 0.22%
CMPVFCompuGroup Medical SE & Co. KGaA $33.66 +11.64% 94.65 $1.74B 3.51%
DWRKFDrägerwerk AG & Co. KGaA $543.70 +0.00% 12.25 $1.75B 2.65%

About Biotest AG

Biotest Aktiengesellschaft, a German biopharmaceutical company established in Dreieich in 1946, specializes in the research, development, production, and global commercialization of advanced biological therapeutics. Its operations are organized into key segments: Therapy, Plasma & Services, and Other. The company’s primary focus areas encompass critical medical needs within hematology (blood disorders), clinical immunology, and intensive care medicine. Biotest offers a comprehensive range of products, including specific treatments for hemophilia like Haemoctin and Vihuma for the acute and prophylactic management of hemophilia A, and Haemonine for similar applications in hemophilia B. Its portfolio also features immunotherapies such as Cytotect CP biotest for cytomegalovirus infections, Fovepta for hepatitis B prophylaxis in neonates, and Hepatect for preventing hepatitis B reinfection. Varitect addresses varicella zoster virus infections, while Intratect and IgG Next Generation are utilized for primary immune and secondary antibody deficiency syndromes, autoimmune conditions, and certain neurological indications. Additionally, Zutectra is available for hepatitis B re-infection prophylaxis following liver transplantation. Further extending its product line, Biotest provides solutions like Albiomin and Biseko to restore and sustain circulating blood volume, Cofact for clotting factor deficiencies, and Fibrinogen for congenital fibrinogen deficiency. Innovative treatments include Trimodulin for community-acquired pneumonia and COVID-19, as well as Pentaglobin for bacterial infections. Known as Biotest Serum-Institut GmbH until its renaming in 1986, the company has been operating as a subsidiary of Grifols, S.A. since January 21, 2022.

Biotest AG is headquartered in DE.

Biotest AG (BIESF) stock trades at $32.00 with a market capitalization of $1.60B. The stock is valued at a price-to-earnings (P/E) ratio of 48.06, price-to-book of 2.40, price-to-sales of 2.18. Over the past 52 weeks the stock has ranged between $30.48 and $32.00, and currently trades at its 52-week high. It pays a dividend yielding 0.16%.

On profitability, Biotest AG generates a return on equity (ROE) of 5.13%, return on capital employed of 7.42%, an operating margin of 13.01%, a net profit margin of 3.64%.

Official website: www.biotest.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides